title: [Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].
abstract: As adjuvant chemotherapy for breast cancer, the addition of taxane to regimens containing anthracycline has been shown to be effective. However, in Japan, it is not probability yet as for safety. We examined the feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer.
  
  
  METHODS
  Node-positive breast cancer patients or node-negative high-risk patients were eligible. The treatment completion rate and toxicity were evaluated in 3 courses of FEC 100 mg/m2 followed by 3 courses of DOC 100 mg/m2.
  
  
  RESULTS
  Twenty-one patients were registered and completion rate was 100%. The relative dose intensity (RDI) was 94.2% for FEC 100 and 97.8% for DOC 100. Grade 3 or higher neutropenia observed in 38% and febrile neutropenia developed in 14%. Non-hematological toxicities were slight.
  
  
  CONCLUSIONS
  The regimen of FEC 100 followed by DOC 100 was safe in adjuvant chemotherapy for breast cancer in our country.
authors: Division of General Surgery, Shiga University of Medical Science.
authors: Hajime
authors: H
authors: Abe
authors: Tomoko
authors: T
authors: Umeda
authors: Makiko
authors: M
authors: Tanaka
authors: Yuki
authors: Y
authors: Kawai
authors: Tsuyoshi
authors: T
authors: Mori
authors: Hirotomi
authors: H
authors: Cho
authors: Yoshihiro
authors: Y
authors: Kubota
authors: Eiji
authors: E
authors: Mekata
authors: Yoshimasa
authors: Y
authors: Kurumi
authors: Tohru
authors: T
authors: Tani
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005240:Feasibility Studies; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil